# Irinotecan and Taxotere With Radiotherapy as Preoperative Treatment in Resectable Esophageal Cancer

> **NCT00318903** · PHASE2 · COMPLETED · sponsor: **University of Alabama at Birmingham** · enrollment: 25 (actual)

## Conditions studied

- Esophageal Cancer
- Cancer of the Esophagus
- Esophagus Cancer
- Esophageal Neoplasm
- Cancer of Esophagus

## Interventions

- **DRUG:** Irinotecan (drug)
- **DRUG:** Taxotere (drug)
- **PROCEDURE:** Radiotherapy (procedure)
- **PROCEDURE:** Esophagectomy (procedure)

## Key facts

- **NCT ID:** NCT00318903
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-01
- **Primary completion:** —
- **Final completion:** 2006-04
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2023-05-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00318903

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00318903, "Irinotecan and Taxotere With Radiotherapy as Preoperative Treatment in Resectable Esophageal Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00318903. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*